TCR, polypeptide, expression vector, host cell, pharmaceutical composition and method for obtaining TCR
US12221466B2 · kind B2 · utility
0Cited by
0References
17Claims
0Family size
Assignees
Inventor
Key dates
| Filing date | May 9, 2022 |
| Grant date | Feb 11, 2025 |
| Priority date | — |
| Expiry date | Oct 4, 2042 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2239/55
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed in the present application is a T cell receptor (TCR) capable of specifically recognizes MAGE-A4 antigenic peptide, including a TCRα Polypeptide having at least 90% identity with any one selected from a group consisting of sequences of SEQ ID No: 1 to SEQ ID No: 30 and a TCRβ polypeptide having at least 90% identity with any one selected from a group consisting of sequences of SEQ ID No: 31 to SEQ ID No: 60, in which the TCRα polypeptides are in one-to-one correspondence with the TCRβ polypeptides in order.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.